

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 17, 2023

Sandesh Seth Chairman and Chief Executive Officer Actinium Pharmaceuticals, Inc. 100 Park Ave., 23rd Floor New York, NY 10017

> Re: Actinium Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273911

Dear Sandesh Seth:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Jayun Koo